Company intelligence / Profile preview

Simcere Zaiming

Ownership: Private
Development stage: Phase 3

Overview

Simcere Zaiming has successfully launched several products in China including COSELA®, Enweida®, Endostar®, and Enlituo®. The company has multiple clinical-stage candidates including SIM0505 (CDH6 ADC) with IND approvals in both China and the US, SIM0500 (trispecific antibody) in Phase 1 for multiple myeloma, SIM0508 (Pol θ inhibitor) with clinical trial approvals in China and the US, and a partnership for TGRX-326 (ALK/ROS1 dual inhibitor)

Therapeutic areas: Oncology
Modalities: Antibody-Drug Conjugates (ADCs)Trispecific AntibodiesSmall Molecule InhibitorsMonoclonal Antibodies
Industry: Biotech

Drug pipeline

17 assets

suvemcitug

16 more assets in the full pipeline.

Partnerships

AbbVie (for SIM0500)TargetRx (for TGRX-326)Apexigen (for Suvemcitug)

Beyond the preview

Go deeper on Simcere Zaiming.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simcere Zaiming.